Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

24.05.24 17:57 Uhr

Werte in diesem Artikel
Aktien

3,33 EUR -0,01 EUR -0,36%

47,13 EUR -0,03 EUR -0,06%

Indizes

PKT PKT

1.581,4 PKT -32,4 PKT -2,00%

508,6 PKT -9,5 PKT -1,84%

26.351,5 PKT -236,6 PKT -0,89%

26.075,1 PKT -697,8 PKT -2,61%

12.807,9 PKT -347,5 PKT -2,64%

7.184,9 PKT -147,9 PKT -2,02%

Shares of Puma Biotechnology, Inc. PBYI have plunged 38.4% in the past three months compared with the industry’s decline of 4.8%.The company’s sole marketed product, Nerlynx (neratinib), is approved for the treatment of early-stage HER2-positive breast cancer in patients who have been previously treated with Roche’s RHHBY Herceptin-based adjuvant therapy.Demand for Nerlynx has been declining in recent quarters. Owing to this, sales of the drug have been falling over the past couple of quarters. Being the only marketed product, Nerlynx sales comprise the majority of PBYI’s top line.Declining sales of Nerlynx have been the primary reason for the stock’s decline.Image Source: Zacks Investment ResearchWhile the breast cancer market holds immense commercial potential, Nerlynx faces intense competition in the targeted space. Approved treatments include Roche's Herceptin and Novartis' Tykerb. A few other companies are also developing treatments targeting this disease.The declining sales, coupled with stiff competition in the target market, remain a headwind for PBYI.Also, currently, Puma Biotechnology has no approved product in its portfolio other than Nerlynx. As a result, the company is heavily dependent on Nerlynx for growth.We note that Puma Biotechnology in-licensed global development and commercialization rights for alisertib, an aurora kinase A inhibitor, from Japan’s Takeda in 2022. The company is currently focusing on developing alisertib for the treatment of various cancer indications.PBYI believes that alisertib has huge potential in HR-positive, HER2-negative breast cancer, triple-negative breast cancer, head and neck cancer and small cell lung cancer.The company is conducting ALISCA-Lung1, a phase II study (PUMA-ALI-4201) evaluating alisertib as a monotherapy for the treatment of patients with extensive stage small cell lung cancer. Interim data from the study is expected in the fourth quarter of 2024.PBYI also expects to begin the phase II ALISCA-Breast1 study on alisertib for treating human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer in the fourth quarter of 2024.If successfully developed, alisertib, has the potential to boost the company’s position in the anticancer drug market and lower its heavy dependence on Nerlynx for revenues.Puma Biotechnology, Inc. Price Puma Biotechnology, Inc. price | Puma Biotechnology, Inc. QuoteZacks Rank & Stocks to ConsiderPuma Biotechnology currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the healthcare sector are Krystal Biotech, Inc. KRYS and Marinus Pharmaceuticals, Inc. MRNS, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have improved from $1.61 to $2.06. Earnings per share estimates for 2025 have improved from $3.69 to $4.33. Year to date, shares of KRYS have surged 31.9%.KRYS’s earnings beat estimates in two of the trailing four quarters and missed the same on the remaining two occasions, the average negative surprise being 21.46%.In the past 60 days, estimates for Marinus Pharmaceuticals’ 2024 loss per share have narrowed from $2.44 to $1.87, while loss per share estimates for 2025 have narrowed from $1.97 to 90 cents. Year to date, shares of MRNS have plunged 88%.MRNS’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same once, the average surprise being 3.27%.Where Will Stocks Go…If Biden Wins? If Trump Wins?The answers may surprise you.Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…1. Medical manufacturer has gained +11,000% in the last 15 years.2. Rental company is absolutely crushing its sector.3. Energy powerhouse plans to grow its already large dividend by 25%.4. Aerospace and defense standout just landed a potentially $80 billion contract.5. Giant Chipmaker is building huge plants in the U.S. Hurry, Download Special Report FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI): Free Stock Analysis Report Marinus Pharmaceuticals, Inc. (MRNS): Free Stock Analysis Report Krystal Biotech, Inc. (KRYS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf IN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf IN

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu PUMA SE

Analysen zu PUMA SE

DatumRatingAnalyst
05.06.2024PUMA SE Sector PerformRBC Capital Markets
03.06.2024PUMA SE HoldJefferies & Company Inc.
03.06.2024PUMA SE Sector PerformRBC Capital Markets
17.05.2024PUMA SE Equal WeightBarclays Capital
10.05.2024PUMA SE BuyHauck Aufhäuser Lampe Privatbank AG
DatumRatingAnalyst
10.05.2024PUMA SE BuyHauck Aufhäuser Lampe Privatbank AG
10.05.2024PUMA SE BuyWarburg Research
09.05.2024PUMA SE BuyDeutsche Bank AG
09.05.2024PUMA SE BuyGoldman Sachs Group Inc.
08.05.2024PUMA SE AddBaader Bank
DatumRatingAnalyst
05.06.2024PUMA SE Sector PerformRBC Capital Markets
03.06.2024PUMA SE HoldJefferies & Company Inc.
03.06.2024PUMA SE Sector PerformRBC Capital Markets
17.05.2024PUMA SE Equal WeightBarclays Capital
10.05.2024PUMA SE Sector PerformRBC Capital Markets
DatumRatingAnalyst
20.09.2021PUMA SE VerkaufenDZ BANK
06.07.2021PUMA SE VerkaufenDZ BANK
28.04.2021PUMA SE VerkaufenDZ BANK
23.04.2021PUMA SE VerkaufenDZ BANK
09.04.2021PUMA SE VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für PUMA SE nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"